Additionally, Ganetespib enhances the sensitivity of mantle cell lymphoma (MCL) cells to the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib, particularly in resistant cancer cells. The gene discussed is BTK; the disease is mantle cell lymphoma.